Obstetrics & Gynecology Doctors in Ketchikan, AK Accepting Medicare

4 Obstetrics & Gynecology doctors found. Showing 1 - 4

Dr. John E. Varallo, MD, MPH Obstetrics & Gynecology Medicare: Medicare Enrolled Practice Location: 3100 Tongass Ave, Ketchikan, AK 99901 Phone: 907-228-8300    Fax: 907-228-8518

Dr. Myra C Dove, MD Obstetrics & Gynecology Medicare: Medicare Enrolled Practice Location: 3100 Tongass Ave, Ketchikan, AK 99901 Phone: 907-228-7688    Fax: 907-228-8468

Dr. Alan L Christensen, M.D. Obstetrics & Gynecology Medicare: Medicare Enrolled Practice Location: 3100 Tongass Ave, Ketchikan, AK 99901 Phone: 907-228-7688    Fax: 907-228-8468

Dr. Andrew Franklin Zink, DO Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: 3100 Tongass Ave, Ketchikan, AK 99901 Phone: 907-228-7660

News Archive

Time-restricted eating may prove to be a dietary intervention against breast cancer

Changing when you eat rather than what you eat may prove to be a dietary intervention against breast cancer, suggests a new mouse study to be presented Saturday at ENDO 2019, the Endocrine Society's annual meeting in New Orleans, La.

New training network project to develop medical statisticians to achieve drug development success

A new £2.7 million international training network project, led by a team at Lancaster University, will develop a generation of medical statisticians dedicated to achieving early stage drug development success.

New position paper examines benefits of actual, virtual natural environments on human health

A new position paper by researchers at the European Centre for the Environment and Human Health and the University of Birmingham has compared the benefits of interaction with actual and virtual natural environments and concluded that the development of accurate simulations are likely to be beneficial to those who cannot interact with nature because of infirmity or other limitations: but virtual worlds are not a substitute for the real thing.

Vertex reports 75% patients with HCV achieve viral cure with 12-week telaprevir-based combination regimen

Vertex Pharmaceuticals Incorporated today announced that 75% of people chronically infected with genotype 1 hepatitis C virus (HCV) who had not previously been treated achieved a sustained viral response (SVR or viral cure) after receiving a 12-week telaprevir-based combination regimen, followed by treatment with pegylated-interferon and ribavirin alone, in the Phase 3 ADVANCE trial.

Gene-therapy trial to restore hearing in deaf mice

Researchers have found long-sought genes in the sensory hair cells of the inner ear that, when mutated, prevent sound waves from being converted to electric signals - a fundamental first step in hearing. The team, co-led by Jeffrey Holt, PhD, in the department of otolaryngology at Children-s Hospital Boston, and Andrew Griffith, MD, PhD, of the NIH-s National Institute on Deafness and other Communication Disorders (NIDCD), then restored these electrical signals in the sensory cells of deaf mice by introducing normal genes.

Read more Medical News

› Verified 4 days ago